糖皮质激素与老年COVID-19患者院内死亡相关:倾向匹配队列研究
倾向评分匹配984例后分析显示,使用糖皮质激素与院内死亡风险升高独立相关(OR=2.61,95%CI 1.63-4.20),匹配队列院内死亡率为32.3%。
要点
- 老年COVID-19住院患者使用糖皮质激素与院内死亡风险升高相关(OR=2.61)。
- 接受糖皮质激素者68.3%出现至少一种不良反应,谵妄占32.9%。
- 年龄、CCI、室内空气血氧饱和度<90%、CRP及淋巴细胞低值亦与死亡相关。
核心结论
- 在这项老年COVID-19住院患者的多中心匹配队列研究中,使用糖皮质激素与院内死亡显著相关。
研究设计与样本
- 采用倾向评分匹配及多因素分析,匹配后984例(接受与未接受糖皮质激素各492例)。
主要发现
- 匹配队列院内死亡率为32.3%。
- 多因素分析显示糖皮质激素使用与院内死亡概率升高相关(OR=2.61,95%CI 1.63-4.20)。
- 与院内死亡相关的其他因素包括年龄(OR=1.04,95%CI 1.01-1.07)、CCI(OR=1.18,95%CI 1.07-1.29)、日常生活活动能力(OR=0.85,95%CI 0.75-0.95)、室内空气血氧饱和度<90%(OR=2.15,95%CI 1.45-3.17)、C反应蛋白水平(OR=2.06,95%CI 1.69-2.51)及最低淋巴细胞计数(OR=0.49,95%CI 0.38-0.63)。
- 535例接受糖皮质激素的患者中,68.3%出现至少一种糖皮质激素不良反应,包括谵妄(32.9%)、继发感染(32.7%)和糖尿病失代偿(14.4%)。
临床怎么用
- 老年COVID-19患者使用糖皮质激素需权衡院内死亡风险升高及谵妄、继发感染、糖尿病失代偿等不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few data are available on the prognosis of older patients who received corticosteroids for COVID-19. We aimed to compare the in-hospital mortality of geriatric patients hospitalized for COVID-19 who received corticosteroids or not. METHODS: We conducted a multicentric retrospective cohort study in 15 acute COVID-19 geriatric wards in the Paris area from March to April 2020 and November 2020 to May 2021. We included all consecutive patients aged 70 years and older who were hospitalized with confirmed COVID-19 in these wards. Propensity score and multivariate analyses were used. RESULTS: Of the 1 579 patients included (535 received corticosteroids), the median age was 86 (interquartile range 81-91) years, 56% of patients were female, the median Charlson Comorbidity Index (CCI) was 2.6 (interquartile range 1-4), and 64% of patients were frail (Clinical Frailty Score 5-9). The propensity score analysis paired 984 patients (492 with and without corticosteroids). The in-hospital mortality was 32.3% in the matched cohort. On multivariate analysis, the probability of in-hospital mortality was increased with corticosteroid use (odds ratio [OR] = 2.61 [95% confidence interval (CI) 1.63-4.20]). Other factors associated with in-hospital mortality were age (OR = 1.04 [1.01-1.07], CCI (OR = 1.18 [1.07-1.29], activities of daily living (OR = 0.85 [0.75-0.95], oxygen saturation < 90% on room air (OR = 2.15 [1.45-3.17], C-reactive protein level (OR = 2.06 [1.69-2.51], and lowest lymphocyte count (OR = 0.49 [0.38-0.63]). Among the 535 patients who received corticosteroids, 68.3% had at least one corticosteroid side effect, including delirium (32.9%), secondary infections (32.7%), and decompensated diabetes (14.4%). CONCLUSIONS: In this multicentric matched-cohort study of geriatric patients hospitalized for COVID-19, the use of corticosteroids was significantly associated with in-hospital mortality.
引用
- Lidou-Renault V, Baudouin E, Courtois-Amiot P, et al. Corticosteroid Therapy in COVID-19 Associated With In-hospital Mortality in Geriatric Patients: A Propensity Matched Cohort Study. J Gerontol A Biol Sci Med Sci. 2022. PMID: 35395678. doi:10.1093/gerona/glac084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。